+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 115 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5012695
UP TO OFF until Mar 31st 2024
The cell therapy market is expected to witness a CAGR of 17.05% over the forecast period.

The impact of the COVID-19 pandemic on the cell therapy market is expected to be significant as most companies have been focusing on the development of cell-based therapies for COVID-19 treatment. For instance, in April 2020, Calidi Biotherapeutics Inc. revealed that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells Inc. (PSC), received the Food and Drug Administration approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. The impact of COVID-19 is also expected to have a positive impact on the studied market as most pharmaceutical, biotechnology, and research institutes have been focusing on the development of cell therapy-based treatment against COVID-19. For instance, according to the study published in Stem Cell Research & Therapy volume on ‘When stem cells meet COVID-19: recent advances, challenges and future perspectives’ published in January 2022, stem cell therapy and stem cell-derived organoid models have got a lot of attention as a new treatment and research method for COVID-19, and stem cells play a role in the battle against COVID-19. This will open up further opportunities for the market players to launch new products, which is expected to drive the market growth during the forecast period.

The cell therapy market is anticipated to witness healthy growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.

Chronic diseases and conditions are on the rise worldwide. As per the International Diabetes Federation Diabetes Altas, in 2021, nearly 573 million adults globally were living with diabetes worldwide, and the number is expected to reach 643 million by 2030 and 783 million by 2045.

Therefore, the increasing prevalence of chronic conditions, government assistance, and numerous companies investing heavily in stem cell therapy research and development are predicted to stimulate industry growth. The proven effectiveness of cell therapy products, coupled with the increasingly favorable guidelines on cell therapy research and manufacturing, is likely to positively impact the market growth over the forecast period. On the other hand, the high cost associated with cell therapies is expected to hinder market growth.

Key Market Trends

The Allogeneic Therapies Segment is Expected to Account for a Significant Share in the Cell Therapy Market

Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore, the increasing inclination of physicians toward the therapeutic use of allogeneic therapies and rising awareness about the use of cord cells and tissues across various therapeutic areas are some of the major factors driving the growth. Allogenic cells have benefits as they produce their own immune stem cells that kill the cancer cells that remain even after high-dose treatment with cytotoxic drugs. This response is called a graft-versus-cancer effect, and this is used in the prevention or treatment of cancer relapse. The aforementioned factors are expected to drive the market over the forecast period.

The rising number of clinical trials required to gain regulatory approval for new medications to advance patient care is expected to boost the segment growth. For instance, ALLO-501, ALLO-501A, ALLO-715, UCART19, and UCART19 by Allogene provide growth opportunities for the segmental growth.

Moreover, in January 2020, Allogene Therapeutics Inc. and SpringWorks Therapeutics Inc. entered a clinical trial collaboration agreement for the evaluation of ALLO-715, along with Nirogacestat, in multiple myeloma patients.

Thus, owing to the rising number of research studies on allogenic therapy for cancer and associated benefits, the studied segment is anticipated to register steady growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is estimated to retain the largest share of the cell therapy market due to the presence of a strong regulatory framework to promote cellular therapy development, the existence of industry key players, and the presence of leading universities that support the research activities in the United States. Factors attributing to the high growth of the market in the region include the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.

Rising investments from market players for the development and expansion of cell-based therapies in the United States are expected to drive the market in North America. For instance, in January 2022, Cellino Biotech, an autonomous cell therapy manufacturing company, raised USD 80 million Series A financing round. Cellino plans to expand access to stem cell-based therapies with the intention to build the first autonomous human cell foundry in 2025. The applications of stem cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world. This has led to increased investments by market players in the development of novel therapies in this area. ​

Furthermore, improved results of cell therapy products for the treatment of cancers will lead to a rise in product development, which is expected to drive the growth of this market. For instance, in June 2021, Gilead’s Yescarta CAR T-cell therapy improved event-free survival by 60% in second-line relapsed or refractory large B-cell lymphoma patients. In addition, in June 2021, Bristol-Myers Squibb reported positive topline results from the phase 3 TRANSFORM Trial evaluating Breyanzi (lisocabtagene maraleucel) in second-line relapsed or refractory large B-cell lymphoma.

Therefore, rising investments and research initiatives by the key market players and positive results of cell therapies are the factors expected to drive the growth of this market in North America.

Competitive Landscape

The cell therapy market is moderately competitive, with the presence of a considerable number of companies. The major companies in this market are evolving through various strategies such as investment in research and development, acquisitions, partnerships, and collaborations to secure their market positions. The major companies of the studied market are Pharmicell Co. Ltd, Corestem Inc., Chiesi Farmaceutici SpA, Tegoscience, Anterogen Co. Ltd, and TiGenix (Takeda Pharmaceuticals), among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Conditions
4.2.2 Rising Adoption of Regenerative Medicine
4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies
4.3 Market Restraints
4.3.1 High Cost of Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 Type
5.1.1 Autologous
5.1.2 Allogeneic
5.2 Therapy
5.2.1 Mesenchymal Stem Cell Therapy
5.2.2 Fibroblast Cell Therapy
5.2.3 Hematopoietic Stem Cell Therapy
5.2.4 Other Therapies
5.3 Application
5.3.1 Musculoskeletal
5.3.2 Malignancies
5.3.3 Cardiovascular
5.3.4 Dermatology and Wounds
5.3.5 Other Applications
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Anterogen Co. Ltd
6.1.2 Tego Science
6.1.3 Chiesi Farmaceutici SpA
6.1.4 Corestem Inc.
6.1.5 Pharmicell Co. Ltd
6.1.6 Fibrocell Technologies Inc.
6.1.7 Nipro Corporation
6.1.8 MEDIPOST Co. Ltd
6.1.9 TiGenix (Takeda Pharmaceuticals)
6.1.10 Stempeutics Research Pvt. Ltd
6.1.11 Gilead Sciences Inc. (Kite Pharma Inc.)
6.1.12 Allogene Therapeutics Inc.
6.1.13 Novartis AG
6.1.14 Vericel Corporation
6.1.15 Organogenesis Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Anterogen Co. Ltd
  • Tego Science
  • Chiesi Farmaceutici SpA
  • Corestem Inc.
  • Pharmicell Co. Ltd
  • Fibrocell Technologies Inc.
  • Nipro Corporation
  • MEDIPOST Co. Ltd
  • TiGenix (Takeda Pharmaceuticals)
  • Stempeutics Research Pvt. Ltd
  • Gilead Sciences Inc. (Kite Pharma Inc.)
  • Allogene Therapeutics Inc.
  • Novartis AG
  • Vericel Corporation
  • Organogenesis Inc.